AstraZeneca announced that it has entered into an agreement with Tillotts Pharma AG , part of the Zeria Group, for...
Crohn's disease - Induction of remission in patients with mild to moderate active Crohn's disease affecting the ileum and/or the ascending colon. Microscopic colitis - Induction of remission in patients with active microscopic colitis Maintenance of remission in patients with microscopic colitis.
Ulcerative colitis involving rectal and recto-sigmoid disease.
AstraZeneca has announced that it has entered into an agreement with Perrigo Company plc for the divestment of US rights...
Cortiment is indicated in adults for: • induction of remission in patients with mild to moderate active ulcerative colitis (UC) where 5-ASA treatment is not sufficient. • induction of remission in patients with active microscopic colitis (MC).
The European Commission (EC) has granted marketing authorization for Inlyta (axitinib) from Pfizer for the treatment of adult patients with...
Astellas Pharma Europe has filed EC 905 its fixed dose combination of Flomaxtra XL (tamsulosin) and Vesicare(solifenacin)in the Netherlands under...
Sandoz, announces that the European Commission (EC) has granted marketing authorization for Pyzchiva (biosimilar ustekinumab), developed and registered by Samsung Bioepis
AstraZeneca announced that the European Commission (EC) has on 6 December 2013 granted Marketing Authorisation to Fluenz Tetra. Fluenz Tetra...